Kathryn Arendt, MD
Gynecology · Kirkland, WANPI 1639157613
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 68.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $12,758 and has fallen 92.5% since, to $957 in 2025. Among gynecology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $175.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$17K
- Coloplast$2K
- Bluewind Medical$2K
- Caldera Medical, Inc$1K
- Boston Scientific$1K
- Medtronic$588
- plus $2K from 15 others
What the payments were for
- Consulting fees$9,52838%
- Speaking & faculty fees$8,13033%
- Travel & lodging$1,7297%
- Food & beverage$3,91916%
- Education$1,2675%
- Gifts$3011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $16,962 |
| Coloplast | 12 | $1,790 |
| Bluewind Medical | 8 | $1,559 |
| Caldera Medical, Inc | 13 | $1,363 |
| Boston Scientific | 24 | $1,098 |
| Medtronic(2 entities) | 7 | $588 |
| Sumitomo Pharma America, Inc. | 10 | $368 |
| Mayne Pharma Commercial LLC | 29 | $331 |
| Astellas Pharma US Inc | 4 | $184 |
| Urovant Sciences Inc | 7 | $109 |
| Femselect Inc. | 1 | $104 |
| Antares Pharma, Inc. | 6 | $93 |
| Therapeuticsmd, Inc. | 5 | $84 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $67 |
| Rochester Medical Corporation | 2 | $39 |
| Bayer | 2 | $36 |
| Laborie Medical Technologies Corp. | 1 | $36 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Convatec Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$16,962
- REVI$1,493
- RESTORELLE$1,200
- Desara$894
- INTERSTIM$558
- SOLYX$455
- ALTIS$303
- GENERAL KIDNEY STONE DISEASE$258
- GEMTESA$145
- Veozah$125
- EnPlace$104
- ADVANTAGE$102
How this compares
$24,874 in reported general payments places this provider in the 95th percentile of 31 gynecology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 99 | $73,693 |
| Estradiol | 297 | $41,291 |
| MyrbetriqMirabegron | 59 | $40,762 |
| EstringEstradiol | 59 | $31,081 |
| ImvexxyEstradiol | 19 | $10,670 |
| Estradiol (Twice Weekly)Estradiol | 70 | $6,826 |
| DottiEstradiol | 34 | $5,764 |
| PremarinEstrogens, Conjugated | 14 | $5,308 |
| Methenamine Hippurate | 30 | $1,710 |
| Trospium Chloride ErTrospium Chloride | 16 | $1,569 |
| Estradiol (Once Weekly)Estradiol | 22 | $1,386 |
| ProgesteroneProgesterone, Micronized | 47 | $1,120 |
| ValacyclovirValacyclovir Hcl | 15 | $965 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $579 |
| Ondansetron Hcl | 22 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $368 | $73,69399 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $40,76259 claims |
| PfizerEstring, Premarin | $15 | $36,38973 claims |
| Therapeuticsmd, Inc.Imvexxy | $84 | $10,67019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 gynecology providers in Washington.
Other gynecology in Kirkland
- Rohan HattiangadiKirkland$2K
- Robin KrollSeattle$283K
- John LenihanTacoma$17K
- Molly DorrohTacoma$5K
- Cynthia McNallyVancouver$4K
- Brooke WinnerSeattle$4K
- Parisa KhalighiSeattle$2K
- Peter BrandonSeattle$2K
- Megan LoringSeattle$1K
- Michelle FearsPuyallup$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.